BRAF and melanoma: Incorporating XGBoost significantly improved performance, reaching an AUC of 0.824 (SD=0.043) during cross-validation and 0.772 (95 % CI: 0.650–0.886) on the independent set—representing a new state-of-the-art for image-only BRAF mutation prediction in melanoma.